Organization (Academic)
University of South Alabama
ClinicalTrials.gov lists University of South Alabama as lead sponsor of 29 trials. It has 8 active development programs and 13 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers University of South Alabama: 29 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (57)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 4 |
| Diabetes Mellitus | 3 |
| Obesity | 3 |
| Premature Birth | 3 |
| Bronchopulmonary Dysplasia | 2 |
Showing 5 of 57 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Topical Steroid | Vulvar Lichen Sclerosus | Phase 2/3 | 1 |
| Ibuprofen and acetaminophen | Ductus Arteriosus, Patent | Phase 2 | 1 |
| Ibuprofen and acetaminophen | Heart Defects, Congenital | Phase 2 | 1 |
| Ibuprofen and acetaminophen | Premature Birth | Phase 2 | 1 |
| Ibuprofen and acetaminophen | Ventilator-Induced Lung Injury | Phase 2 | 1 |
Showing 5 of 8 active programs.
Approved assets (13)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| LUBIPROSTONE | 2 |
| DEXMEDETOMIDINE | 1 |
| Ketorolac | 1 |
| Ketorolac Tromethamine | 1 |
| REFRESH TEARS | 1 |
Showing 5 of 13 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 11% hit target (n=9) | 30% on time (n=10) |
Journals published in (81)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of physiology. Lung cellular and molecular physiology | 6 |
| International journal of antimicrobial agents | 5 |
| Journal of immunology (Baltimore, Md. : 1950) | 4 |
| Nature | 3 |
| Obstetrics and gynecology | 3 |
Showing 5 of 81 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 66 | 13 | 2024-09-03 |
Financing and grant events (115)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-03 | NIH grant | 761,262 | Reporter |
| 2025-09-11 | NIH grant | 124,386 | Reporter |
| 2025-08-28 | NIH grant | 461,490 | Reporter |
| 2025-08-11 | NIH grant | 906,166 | Reporter |
| 2025-07-12 | NIH grant | 554,585 | Reporter |
Showing 5 of 115 events.
Organization relationships (33)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Arizona's Public Universities | Co sponsors trial with | 1 |
| Sarasota Memorial Health Care System | Co sponsors trial with | 1 |
| Ascension | Co sponsors trial with | 1 |
| The University of Texas System | Co sponsors trial with | 1 |
| Sanford Health | Co sponsors trial with | 1 |
Showing 5 of 33 relationships.
Latest dated events (230)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-03 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 230 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| UNIVERSITY OF SOUTH ALABAMA | Certificate of accreditation | Active |
| UNIVERSITY OF SOUTH ALABAMA | Certificate of waiver | Active |
| UNIVERSITY OF SOUTH ALABAMA | Certificate for PPM procedures | Terminated |
Biomarker capability evidence (15)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| G6PD | Trial sponsor | Named in trial exclusion criteria |
| H6PD | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 15 evidence rows.
Biomarkers this organization publishes on (427)
Shown in this order: most publications first.
Showing 5 of 427 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.